Brain–computer interface

Neurorehabilitation Devices Industry Analysis and 95 Competitor Profiles, 2022-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 21, 2022

Neurorehabilitation devices are witnessing extensive use in clinical settings, cognitive care, healthcare centers and research institutes.

Key Points: 
  • Neurorehabilitation devices are witnessing extensive use in clinical settings, cognitive care, healthcare centers and research institutes.
  • This segment currently accounts for a 25% share of the global Neurorehabilitation Devices market.
  • The market growth is facilitated by rising awareness about advantages of neurorehabilitation devices coupled with presence of a robust healthcare infrastructure.
  • The neurorehabilitation wearable devices segment is poised to maintain its positive trajectory due to availability of innovative options offering better alternatives to traditional neurorehabilitation approaches.

AE Studio Wins First Place in Neural Latents Benchmark Challenge

Retrieved on: 
Wednesday, January 12, 2022

VENICE, Calif., Jan. 12, 2022 /PRNewswire/ -- AE Studio , a team of developers, designers, and data scientists, has earned the recognition as the world's top machine learning team in BCI (Brain Computer Interface) following its win in the Neural Latents Benchmark Challenge .

Key Points: 
  • VENICE, Calif., Jan. 12, 2022 /PRNewswire/ -- AE Studio , a team of developers, designers, and data scientists, has earned the recognition as the world's top machine learning team in BCI (Brain Computer Interface) following its win in the Neural Latents Benchmark Challenge .
  • AE Studio is developing the software component of BCI machine learning algorithms to interpret brain activity (neural decoding).
  • Developing BCI technology to increase human agency has always been a goal since AE was created, and we're excited that we're getting exponentially better, faster than we could have imagined," said Judd Rosenblatt, CEO at AE Studio.
  • AE (Agency Enterprise) is currently hiring the best machine learning engineers and neuroscientists on planet earth to maximize human agency.

Edge AI Software Market Is Projected To Reach USD 8049.8 Million by 2027 | CAGR: 29.8%: Astute Analytica

Retrieved on: 
Monday, November 22, 2021

Smart speakers and voice assistants that are embedded with complicated edge AI software provides more interactive human interface.

Key Points: 
  • Smart speakers and voice assistants that are embedded with complicated edge AI software provides more interactive human interface.
  • 5G coupled with Edge AI software aims to provide a better customer experience, increase business efficiency, and generate higher revenue and more opportunities.
  • For example, recently Telstra collaborated with amazon web services (AWS) to combine AWS's edge AI technology with Telstra's 5G network.
  • In 2021, Paravision released a toolkit that is embedded with edge AI software that provides various facial recognition functions.

Optomec Reports $2 Million in Orders from Leading Media and Technology OEM

Retrieved on: 
Monday, November 1, 2021

Optomec Inc., the leading supplier of 3D Additive Electronics manufacturing solutions today announced the receipt of orders totaling approximately $2 Million from a premier supplier of digital connectivity solutions.

Key Points: 
  • Optomec Inc., the leading supplier of 3D Additive Electronics manufacturing solutions today announced the receipt of orders totaling approximately $2 Million from a premier supplier of digital connectivity solutions.
  • The recent orders include the delivery of three (3) Aerosol Jet 3D Electronics Printers, together with related Software and Digital Products, plus professional services to support their application development.
  • The customer is leveraging Optomecs patented Aerosol Jet process for the development and ultimate production of a variety of next generation Wearable devices.
  • LENS is a registered trademark of Sandia National Labs; Aerosol Jet is a registered trademark of Optomec, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005906/en/

Paradromics announces NIH award to fund translational and early-stage clinical research

Retrieved on: 
Thursday, October 14, 2021

The high density arrays developed by Paradromics are capable of recording signals from individual neurons to enable clinical research and therapeutic treatment of many neurological conditions.

Key Points: 
  • The high density arrays developed by Paradromics are capable of recording signals from individual neurons to enable clinical research and therapeutic treatment of many neurological conditions.
  • This grant includes a subaward to Massachusetts General Hospital (MGH) to work with Paradromics on clinical research initiatives.
  • The funding will strengthen the ongoing collaboration between Paradromics and MGH researchers Sydney Cash, MD, PhD, and Leigh Hochberg, MD, PhD.
  • "We are very appreciative of the continued support from the NIH and from our translational neuroscience collaborators at MGH," said Paradromics CEO Matt Angle.

The Inaugural OPPOHack Global Innovation Competition to Announce Outstanding Winners

Retrieved on: 
Friday, August 13, 2021

The final round of the inaugural OPPOHack Global Innovation Competition will finally be broadcasting on the 14th and 15th of August.

Key Points: 
  • The final round of the inaugural OPPOHack Global Innovation Competition will finally be broadcasting on the 14th and 15th of August.
  • The OPPOHack Global Innovation Competition is an initiative organized by OPPO to stimulate entrepreneurs, technology enthusiasts, and scientific experts to come together, share different ideas, and innovate new solutions to better meet people's needs.
  • Hosted by OPPO alongside partner HackHub, the OPPOHack Global Innovation Competition is focused on the three sub-themes of Connected Car System, Immersive Experience (AR/VR & Gaming), and Robotics.
  • OPPO will continue to run the OPPOHack Global Innovation Competition and similar networking events to expand the company's resources for innovation projects, co-investment opportunities, and talent recruitment channels.

Paradromics Raises $20MM in Seed Funding Led by Prime Movers Lab to Advance Brain Computer Interfaces

Retrieved on: 
Thursday, July 22, 2021

AUSTIN, Texas, July 22, 2021 /PRNewswire/ -- Paradromics Inc., a leading developer of high data rate Brain Computer Interfaces (BCI), announced today a $20 million seed funding round led by Prime Movers Lab, including investment from Westcott Investment Group, Dolby Family Ventures, Synergy Ventures, Pureland Global Venture, IT-Farm, and Alpha Edison.

Key Points: 
  • AUSTIN, Texas, July 22, 2021 /PRNewswire/ -- Paradromics Inc., a leading developer of high data rate Brain Computer Interfaces (BCI), announced today a $20 million seed funding round led by Prime Movers Lab, including investment from Westcott Investment Group, Dolby Family Ventures, Synergy Ventures, Pureland Global Venture, IT-Farm, and Alpha Edison.
  • Through this BCI, patients will be able to reconnect with loved ones and achieve greater autonomy through use of a computer.
  • As part of the investment from Prime Movers Lab, Partner Dr. Amy Kruse will be joining the Paradromics Board of Directors.
  • Prime Movers Lab invests in breakthrough scientific startups founded by Prime Movers, the inventors who transform billions of lives.

Inscopix Unveils First Demonstration of Optical-based ‘Wearable’ for Real-Time Measurement of Brain Activity in Non-Human Primates

Retrieved on: 
Tuesday, June 15, 2021

Researchers were able to repeatedly image activity from the same neurons during sessions spanning multiple months allowing for longitudinal tracking of neural ensemble dynamics and their relationship to specific behaviors.

Key Points: 
  • Researchers were able to repeatedly image activity from the same neurons during sessions spanning multiple months allowing for longitudinal tracking of neural ensemble dynamics and their relationship to specific behaviors.
  • Neural activity selective for different directions of arm movements was observed and could be used to decode the animals reach behavior on individual trials with over 85% accuracy.
  • Driven by a North Star of overcoming historic challenges in the field, Inscopix provides validated solutions for real-time mapping of neural activity in brain circuits.
  • Inscopixs partner and customer discoveries help decode the brain, inform deeper understanding of mechanisms of action and enable the screening of drugs based on efficacy.

Synchron Secures $40M in Series B led by Khosla Ventures to Launch U.S. Clinical Trials of Minimally Invasive Brain Computer Interface

Retrieved on: 
Thursday, June 3, 2021

Synchron, a brain interface platform company , today announced that the company has secured $40M in a Series B round of financing led by Silicon Valley venture capital firm Khosla Ventures.

Key Points: 
  • Synchron, a brain interface platform company , today announced that the company has secured $40M in a Series B round of financing led by Silicon Valley venture capital firm Khosla Ventures.
  • Synchron is the leader in minimally invasive implantable brain computer interface (BCI) technology, which utilizes the jugular vein to access the brain.
  • This technology has the potential to positively impact humanity on a vast scale, said Synchron CEO Thomas Oxley, MD, PhD.
  • Synchron, a brain interface platform company, is a leader in the field of implantable neural interface technology.

Precision Neuroscience Raises $12M to Develop Next Generation Brain-Computer Interface Technology

Retrieved on: 
Tuesday, May 25, 2021

Precision Neuroscience is developing a platform for next generation brain-computer interface technology, with a focus on minimally invasive device delivery.

Key Points: 
  • Precision Neuroscience is developing a platform for next generation brain-computer interface technology, with a focus on minimally invasive device delivery.
  • Precision Neuroscience seeks to establish itself as a leader in this space globally.
  • Precision Neuroscience brings together an experienced team that has been developing brain-computer interfaces for nearly two decades.
  • Precision Neuroscience Corporation has offices in New York, California, and Massachusetts, and seeks to expand its team in each location.